Jazz Pharma appoints Dr. Ted Love to board; director Kenneth O'Keefe to retire Dec 1, 2025

Jazz Pharmaceuticals plc

Dr. Ted Love appointed as Class I director effective Dec 1, 2025, term expiring at 2027 AGM.
Love will serve on Audit and Science & Medicine Committees under standard non-employee director compensation.
Director Kenneth O'Keefe retires from Board effective Dec 1, 2025, with no dispute or disagreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.